In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole

Journal of Clinical Microbiology

Volumn 37, Issue 7, 1999, Pages 2343-2345

  Sutton, Deanna A ^a   Sanche, Stephen E ^a   Revankar, Sanjay G ^a   Fothergill, Annette W ^a   Rinaldi, Michael G ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENCY; FUNGICIDAL ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SPECIES DIFFERENCE; TREATMENT OUTCOME;

EID: 0033026744     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.7.2343-2345.1999     Document Type: Article

References (40)

1. Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 103. In V. Lorian (ed), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md.
2. Clancy, C. J., and M. H. Nguyen. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575.
3. Colombo, A. L., D. A. McGough, and M. G. Rinaldi. 1993. Amphotericin B (AMB) tolerance with Aspergillus species, abstr. 748, p. 256. In Programs and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Das, T., P. Vyas, and S. Sharma. 1993. Aspergillus terreus postoperative endophthalmitis. Br. J. Ophthalmol. 77:386-387.
5. Denning, D., A. De Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109-496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80, p. 126. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Drexler, L., M. Rytel, M. Keelan, L. I. Bonchek, and G. N. Olinger. 1980. Aspergillus terreus infective endocarditis on a porcine heterograft valve. J. Thorac. Cardiovasc. Surg. 79:269-274.
7. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109-496) against opportunistic filamentous and dimorphic fungi and common and emerging yeasts. J. Clin. Microbiol. 36:198-199.
8. Espinel-Ingroff, A. 1998. Evaluation of antifungal susceptibility testing parameters for amphotericin B, itraconazole, voriconazole, SCH56592, and BMS-207147 against Aspergillus spp., abstr. J-7, p. 452. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
10. Hara, K. S., and J. H. Ryu. 1989. Disseminated Aspergillus terreus infection in immunocompromised hosts. Mayo Clin. Proc. 64:774-775.
11. Iwen, P. C., M. E. Rupp, A. N. Langnas, E. C. Reed, and S. H. Hinrichs. 1998. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin. Infect. Dis. 26:1092-1097.
12. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In vitro fungicidal activity of voriconazole, itraconazole, and amphotericin B against filamentous fungi, abstr. J-3, p. 451. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Kalina, P. H., and R. J. Campbell. 1991. Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia. Arch. Ophthalmol. 109:102-103.
14. Lass, C., D. Niederwieser, G. Kofler, and M. Dierich. 1996. Isolation of Aspergillus terreus in neutropenic patients associated with resistance to amphotericin B, abstr. 36. In Abstracts of Focus on Fungal Infections 6.
15. Latham, M. N., and J. L. Carpenter. 1982. Aspergillus terreus, a pathogen capable of causing infective endocarditis, pulmonary mycetoma, and allergic bronchopulmonary aspergillosis. Am. Rev. Respir. Dis. 125:769-772.
16. Martin, M. V., J. Yates, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109-496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
17. McCarty, J. M., M. S. Flam, G. Pullen, R. Jones, and S. H. Kassel. 1986. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J. Pediatr. 108:721-724.
18. Moore, C. K., M. A. Hellreich, C. L. Coblentz, and V. L. Roggli. 1988. Aspergillus terreus as a cause of invasive pulmonary aspergillosis. Chest 94: 889-891.
19. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Neumeister, B., W. Hartmann, M. Oethinger, B. Heymer, and R. Marre. 1994. A fatal infection with Alternaria alternata and Aspergillus terreus in a child with agranulocytosis of unknown origin. Mycoses 37:181-185.
22. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
23. Patterson, T. F., W. R. Kirkpatrick, and R. K. McAtee. 1998. The efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis, abstr. B-14, p. 29. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Pfizer Inc. Unpublished data.
25. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingrof, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, and Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
26. Rinaldi, M. G. 1982. Use of potato flakes agar in clinical mycology. J. Clin. Microbiol. 15:1159-1160.
27. Rinaldi, M. G. 1983. Invasive aspergillosis. Rev. Infect. Dis. 5:1061-1077.
28. Rinaldi, M. G., and A. W. Howell. 1988. Antifungal antimicrobics: laboratory evaluation, p. 325-356. In B. Wentworth (ed.), Diagnostic procedures for mycotic and parasitic infections, 7th ed. American Public Health Association, Washington, D.C.
29. Russack, V. 1990. Aspergillus terreus myocarditis: report of a case and review of the literature. Am. J. Cardiovasc. Pathol. 3:275-279.
30. Schett, G., B. Casati, B. Willinger, G. Weinländer, T. Binder, F. Grabenwöger, W. Sperr, K. Geissler, and U. Jäger. 1998. Endocarditis and aortal embolization caused by Aspergillus terreus in a patient with acute lymphoblastic leukemia in remission: diagnosis by peripheral-blood culture. J. Clin. Microbiol. 36:3347-3351.
31. Singh, S. M., S. Sharma, and P. K. Chatterjee. 1990. Clinical and experimental mycotic keratilis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in an animal model. Mycopathologia 112: 127-137.
32. Suseelan, A. V., H. C. Gugnani, and J. O. Ojukwu. 1976. Primary cutaneous aspergillosis due to Aspergillus terreus. Arch. Dermatol. 112:1468.
33. Sutton, D. A., A. W. Fothergill, and M. G. Rinaldi. 1998. Guide to clinically significant fungi. Williams & Wilkins, Baltimore, Md.
34. Sutton, D. A., J. H. Shin, and M. G. Rinaldi. 1998. In vitro resistance of Aspergillus terreus to amphotericin B: data from 64 U.S./Korean clinical isolates, abstr. 15. In Abstracts of Focus on Fungal Infections 8. Imedex USA, Inc., Alpharetta, Ga.
35. Thamlikitkul, V., K. Prachuabmoh, S. Sukroongreung, and S. Danchaivigitr. 1983. Aspergillus terreus endocarditis - a case report. J. Med. Assoc. Thailand 64:723-726.
36. Tiwari, S., S. M. Singh, and S. Jain. 1995. Chronic bilateral suppurative otitis media caused by Aspergillus terreus. Mycoses 38:297-300.
37. Tracy, S. L., M. R. McGinnis, J. E. Peacock, Jr., M. S. Cohen, and D. H. Walker. 1983. Disseminated infection with Aspergillus terreus. Am. J. Clin. Pathol. 80:728-733.
38. Trite, D. M., and G. L. Woods. 1993. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin. Infect. Dis. 16:118-122.
39. van Burik, J. H., R. Colvin, and D. H. Spach. 1998. Cutaneous aspergillosis. J. Clin. Microbiol. 36:3115-3121.
40. Walsh, T. J., G. P. Melcher, M. G. Rinaldi, J. Lecciones, D. McGough, J. Lee, D. Callender, M. Rubin, and P. A. Pizzo. 1990. Disseminated trichosporonosis resistant to amphotericin B. J. Clin. Microbiol. 28:1615-1622.